Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.053|
|52 Week High||AU$0.046|
|52 Week Low||AU$0.094|
|1 Month Change||0%|
|3 Month Change||-8.62%|
|1 Year Change||-42.39%|
|3 Year Change||-75.91%|
|5 Year Change||10.42%|
|Change since IPO||-88.09%|
Recent News & Updates
Biotron (ASX:BIT) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
We're Not Very Worried About Biotron's (ASX:BIT) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
What Can We Conclude About Biotron's (ASX:BIT) CEO Pay?
The CEO of Biotron Limited ( ASX:BIT ) is Michelle Miller, and this article examines the executive's compensation...
|BIT||AU Biotechs||AU Market|
Return vs Industry: BIT underperformed the Australian Biotechs industry which returned 1.5% over the past year.
Return vs Market: BIT underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: BIT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BIT's weekly volatility (7%) has been stable over the past year.
About the Company
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs.
Biotron Fundamentals Summary
|BIT fundamental statistics|
Is BIT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIT income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0046|
|Net Profit Margin||-218.50%|
How did BIT perform over the long term?See historical performance and comparison
Is Biotron undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BIT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BIT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BIT is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: BIT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIT is overvalued based on its PB Ratio (9.6x) compared to the AU Biotechs industry average (4.9x).
How is Biotron forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotron has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Biotron performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIT is currently unprofitable.
Growing Profit Margin: BIT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIT is unprofitable, and losses have increased over the past 5 years at a rate of 10.6% per year.
Accelerating Growth: Unable to compare BIT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: BIT has a negative Return on Equity (-82.69%), as it is currently unprofitable.
How is Biotron's financial position?
Financial Position Analysis
Short Term Liabilities: BIT's short term assets (A$4.3M) exceed its short term liabilities (A$451.2K).
Long Term Liabilities: BIT's short term assets (A$4.3M) exceed its long term liabilities (A$12.3K).
Debt to Equity History and Analysis
Debt Level: BIT is debt free.
Reducing Debt: BIT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BIT has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 2.7% each year.
What is Biotron current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BIT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Michelle Miller, B.Sc., M.Sc., PhD, GCertAppFin (Finsia), serves as Chief Executive Officer of Biotron Ltd. and serves as its Managing Director since June 21, 2002. Dr. Miller served as Investment Mana...
CEO Compensation Analysis
Compensation vs Market: Michelle's total compensation ($USD300.66K) is about average for companies of similar size in the Australian market ($USD302.72K).
Compensation vs Earnings: Michelle's compensation has increased whilst the company is unprofitable.
Experienced Management: BIT's management team is seasoned and experienced (19.3 years average tenure).
Experienced Board: BIT's board of directors are considered experienced (9.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biotron Limited's employee growth, exchange listings and data sources
- Name: Biotron Limited
- Ticker: BIT
- Exchange: ASX
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$37.202m
- Shares outstanding: 701.93m
- Website: https://www.biotron.com.au
Number of Employees
- Biotron Limited
- 66 Hunter Street
- Level 2
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 15:17|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.